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Pediatric kidney transplant recipients experience a
high–risk age window of increased graft loss during
late adolescence and early adulthood that has been
attributed primarily to sociobehavioral mechanisms
such as nonadherence. An examination of how this age
window affects recipients of other organs may inform
the extent to which sociobehavioral mechanisms are
to blame or whether kidney-specific biologic mecha-
nisms may also exist. Graft loss risk across current
recipient age was compared between pediatric kidney
(n¼17,446), liver (n¼ 12,161) and simultaneous liver–
kidney (n¼224) transplants using piecewise-constant
hazard rate models. Kidney graft loss during late
adolescence and early adulthood (ages 17–24 years)
was significantly greater than during ages <17 (aHR
¼ 1.79, 95%CI¼ 1.69–1.90, p< 0.001) and ages >24
(aHR¼1.11, 95%CI¼ 1.03–1.20, p¼0.005). In contrast,
liver graft loss during ages 17–24 was no different than
during ages <17 (aHR¼1.03, 95%CI¼ 0.92–1.16,
p¼ 0.6) or ages >24 (aHR¼ 1.18, 95%CI¼ 0.98–1.42,
p¼ 0.1). In simultaneous liver–kidney recipients, a
trend towards increased kidney compared to liver
graft loss was observed during ages 17–24 years. Late
adolescence and early adulthood are less detrimental
to pediatric liver grafts compared to kidney grafts,
suggesting that sociobehavioral mechanisms alone
may be insufficient to create the high–risk agewindow
and that additional biologic mechanisms may also be
required.
Abbreviations: aHR, adjusted hazard ratio; CAKUT,
congenital anomalies of the kidney and urinary tract;
FSGS, focal segmental glomerular sclerosis; HLA,
human leukocyte antigen; HR, hazard ratio; KT, kidney
transplant; LT, liver transplant; OPTN, organ procure-
ment and transplantation network; PRA, panel reactive
antibody; SLK, simultaneous liver kidney; SRTR,
scientific registry of transplant recipients
Received 26 March 2014, revised 13 August 2014 and
accepted for publication 15 August 2014
Introduction
Graft survival in pediatric kidney transplant (KT) recipients is
strongly associated with recipient age. Recipients of a KT
during their adolescent years have poorer long-term graft
survival compared to recipients in other age groups (1–7).
This disparity in graft survival is likely due to a significantly
increased rate of graft loss during ages 17–24 (8,9), a high–
risk age window through which all pediatric KT recipients
must eventually pass regardless of the age at which
transplantation is performed.
The exact etiology of increased graft loss during the high–
risk age window is unknown. Potential sociobehavioral
explanations include poor adherence to immunosuppres-
sion (10–16), loss of insurance coverage (17–19) and
transitions from pediatric to adult care (14,20–25) during
the patients’ teens to early twenties. Possible biologic
mechanisms that may be specific to kidney grafts, such as
hyperfiltration injury (26) during this period of increased
growth or enhanced susceptibility to immunosuppression
withdrawal, may also be involved or interact with the
proposed sociobehavioral mechanisms. An examination of
the extent to which the high–risk age window is equally
detrimental to pediatric recipients of other transplants may
shed light on which mechanisms are primarily at work in
creating the high–risk agewindow in pediatric KT recipients.
If the mechanisms behind the high–risk age window of KT
recipients are primarily nonbiologic and not specific to the
kidney, one would expect a similar high–risk age window
for liver transplant (LT) recipients given the likely similar
difficulties with adherence, insurance and care transitions.
In addition, one would expect liver and kidney grafts in
pediatric simultaneous liver–kidney (SLK) recipients to be
similarly subject to graft loss during the high–risk age
window. On the other hand, however, differential kidney
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and liver graft loss (especially within the same patient)
would instead suggest that biologic in addition to socio-
behavioral mechanisms must be involved. To better
understand the mechanisms behind the high–risk age
window after pediatric KT, the objective of this studywas to
compare graft loss of pediatric KT, LT and SLK transplant
recipients during the high–risk age window of late
adolescence and early adulthood.
Materials and Methods
Study population
This study utilized data from the Scientific Registry of Transplant Recipients
(SRTR), a national registry of all solid organ transplants. The SRTR includes
data on all donors, waitlisted candidates and transplant recipients in the
United States, submitted by the members of the Organ Procurement and
Transplantation Network (OPTN) and has been described elsewhere (27).
The Health Resources and Services Administration, United States Depart-
ment of Health and Human Services, provides oversight to the activities of
the OPTN and SRTR contractors.
All pediatric (recipient age less than 18 years old at time of transplantation)
kidney-only, liver-only and SLK recipients between October 1987 and
through February 2012 were identified in the SRTR. Based on clinical
knowledge and precedent set by the SRTR program-specific regression
models (available at www.srtr.org), etiology of renal disease was catego-
rized as either focal segmental glomerular sclerosis (FSGS), other glomerular
diseases, congenital anomalies of the kidney and urinary tract (CAKUT) or
other/missing diagnosis. Etiology of liver disease was categorized as either
biliary atresia, metabolic disease, acute hepatic necrosis, malignancy or
other/missing diagnosis.
Outcome ascertainment
All-cause graft survival was defined as the time between transplantation and
either graft loss (marked by either retransplanatation or additionally for KT
recipients, a return to dialysis) or death, censoring for administrative end of
study. All-cause graft survival was examined except where specified. In a
sensitivity analysis, death-censored graft survival, defined as the time
between transplantation and either graft loss (marked by retransplantation or
a return to dialysis) or last date of follow-up with a functioning graft, with
censoring for death and administrative end of study, was also examined.
Death ascertainment was supplemented by linkage to the Social Security
Death Master File; death and graft loss ascertainment were also
supplemented by linkage to data from the Centers for Medicare and
Medicaid Services.
Hazard plots and models
Survival analyses were conditioned on a minimum graft survival of 6 months
to exclude the increased risk of graft loss in the immediate postoperative
period. A sensitivity analysis without this 6 month conditioning was also
performed. Graft failure rates were analyzed within various time intervals;
specifically, seven-year graft failure rates were calculated to determine the
likelihood of graft survival to age 24 given a functioning graft at age 17.
As previously reported (9), the risk of graft loss across age (in other words, the
graft failure rate at a recipient’s current age)wasgraphically explored by plotting
hazard functions against current recipient age (rather than the conventional
posttransplant follow-up time). Age 0 (rather than date of transplantation)
served as the time origin, with late entries into the risk set at each age of
transplantation. The hazard function then provided the current graft failure rate
at a given age conditional on graft survival up to that age. Stratified analyses
were performed across donor type and age at transplantation to explore the
possibility that differences in kidney and liver graft loss across age could be due
to differences in donor type and timing of transplantation.
A piecewise-constant hazard rate model was used to quantify the hazard of
graft loss across posttransplant age. This model is an exponential hazard
model that assumes a constant hazardwithin predefined time segments and
then estimates variation in hazard between time segments (28). Time
segments were chosen as previously described (9). Given that the time axis
in the analysis was current recipient age, the time segments therefore
consisted of periods of age (rather than follow-up time), thus enabling a
closer examination of the high–risk agewindowof ages 17–24 in comparison
to the ages before and after this window.
A multivariable parameterization of the piecewise-constant hazard rate
model was used to compare hazard between posttransplant age categories
while adjusting for potential recipient (sex, race, insurance, diagnosis,
previous transplant history), donor (living vs. deceased, age, and race) and
center-level (pediatric transplant volume) confounders, as well as the year of
transplantation. Dialysis history, peak panel reactive antibody (PRA) and HLA
mismatch were additionally included in KT models. An unadjusted model
was used to compare hazard in the SLK recipient group given the small
sample size. All tests were two sided with statistical significance set at




A total of 17,446 KT recipients, 12,161 LT recipients and
224 SLK recipients underwent transplantation during the
study period (Table 1). Themean age at transplantationwas
older for KT recipients (11.6 years) compared to LT (5.4
years) and SLK (9.6 years) recipients. The most common
known etiologies of disease were CAKUT for KT recipients
and biliary atresia for LT recipients. Nearly half of the KT
recipients received a living donor transplant (49.3%), while
the proportion of LT recipients receiving a living donor
transplant was only 11.6%. HLA mismatch was greater in
LT and SLK recipients (80.2% and 87.2% having 4–6
mismatches, respectively) compared to KT recipients
(55.6% having three or fewer mismatches).
Graft loss in kidney versus liver recipients
Graft loss among pediatric KT recipients (Figure 1A) was
markedly elevated during late adolescence and early
adulthood. In fact, in patients with a functioning graft at
age 17, 43.3% were expected to lose the graft by age 24.
Graft loss among pediatric LT recipients (Figure 1B) was
less pronounced during late adolescence and early
adulthood. In patients with a functioning graft at age 17,
only 15.9% were expected to lose the graft by age 24.
After adjusting for recipient, donor and transplant character-
istics, the hazard of graft loss in KT recipients during ages
17–24 was significantly greater than that during ages 0–17
(adjusted hazard ratio [aHR]: 1.79, 95% CI: 1.69–1.89;
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Table 1: Recipient, donor, transplant and center characteristics for pediatric (<18 years old) kidney, liver and simultaneous liver–kidney
(SLK) transplants performed between 1987–2012
Recipient Kidney (n¼17,446) Liver (n¼12,161) SLK (n¼224)
Mean age (years) (SD) 11.6 (5.1) 5.4 (5.6) 9.6 (5.3)
Female Sex 40.8% 52.2% 52.7%
Race
Caucasian 57.7% 57.7% 63.8%
African American 18.6% 17.9% 9.8%
Other 23.7% 24.3% 26.4%
Public insurance 64.1% 56.1% 54.3%
Etiology of disease Kidney Liver
FSGS 10.4% 1.3%
Other glomerular diseases 14.3% 3.1%
CAKUT 34.9% 25.9%
Other/missing 40.4% 27.9% 69.6% 45.5%
Biliary atresia 42.9% 4.0%
Metabolic disease 11.9% 45.5%
Acute hepatic necrosis 12.6% 2.7%
Malignancy 4.7% 2.2%
Previous transplant
Kidney 11.4% 0.2% 15.6%
Liver 0.4% 14.5% 8.5%
Simultaneous kidney liver 0.1% 0.1% 2.7%
Donor
Mean Age (years) (SD) 29.8 (12.7) 14.6 (14.7) 14.5 (12.4)
Race
Caucasian 68.5% 66.5% 66.5%
African American 12.7% 15.8% 16.1%
Other 18.8% 17.7% 17.4%
Living donor 48.7% 11.6% 0.0%
Transplant
HLA mismatch
0 4.2% 0.5% 0.0%
1–3 51.4% 19.3% 12.8%
4–6 44.4% 80.2% 87.2%
SD, standard deviation; FSGS, focal segmental glomerulosclerosis; CAKUT, congenital anomalies of the kidneys and urinary tract; HLA,
human leukocyte antigen.
Figure 1: Hazard of all-cause graft loss across current recipient age (with 95% confidence interval) among pediatric (A) kidney transplant
recipients and (B) liver transplant recipients.
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p< 0.001) and ages >24 (aHR 1.11, 95% CI: 1.03–1.20;
p¼ 0.005). However, the hazard of graft loss in LT recipients
during ages 17–24 was not significantly different compared
to ages 0–17 (aHR 1.03, 95%CI: 0.92–1.16; p¼ 0.6) or ages
>24 (aHR 1.18, 95% CI: 0.98–1.42; p¼ 0.1).
Similar findings were seen when death-censored graft
survival was instead examined (Figure 2). Likewise,
inferences were unchanged when examining all posttrans-
plant follow-up time (i.e. without conditioning on a
minimum graft survival of 6 months) (Figure 3). Finally,
findings were consistent across donor type and recipient
age at transplantation (Figure 4).
Graft loss in simultaneous liver–kidney recipients
For graft loss amongSLK recipients, kidney graft loss during
ages 17–24 appeared to be accentuated compared to liver
graft loss. In patients with a functioning kidney at age 17,
19.1% were expected to lose the kidney graft by age 24,
and in patients with a functioning liver at age 17, 10.5%
were expected to lose the liver graft by age 24. The hazard
of kidney graft loss for ages 17–24 appeared to be greater
(although not statistically so) compared to ages 0–17
(hazard ratio [HR] 1.47, 95%CI: 0.65–3.32; p¼0.4) andwas
similar to ages >24 (HR 0.82, 95% CI: 0.26–2.58; p¼ 0.7).
The hazard of liver graft loss for ages 17–24 was similar to
both ages 0–17 (HR 0.98, 95% CI: 0.40–2.36; p¼0.9) and
ages >24 (HR 0.86, 95% CI: 0.23–3.24; p¼ 0.8).
Discussion
In this national study of nearly 30 000 pediatric KT, LT and
SLK recipients, we found a significant difference in the rate
at which kidney and liver grafts are lost during the high–risk
age window of late adolescence and early adulthood (8,9).
Graft loss sharply peaks during this time period among KT
recipients; however there is little change in the rate of graft
loss across recipient age among LT recipients. Importantly,
this finding was consistent in sensitivity analyses examin-
ing both death-censored graft survival (to focus specifically
on graft failure given the suspected mechanism of
nonadherence) and all posttransplant follow-up time (to
avoid potential selection bias in examining only those with
graft survival of at least 6 months). Among pediatric SLK
recipients, a trend towards higher rates of kidney graft loss,
compared to liver graft loss, was also observed during the
high–risk age window, although the small sample size
limited definitive conclusions.
The increased risk of graft loss during late adolescence and
early adulthood among pediatric KT recipients has been
attributed to lack of adherence to immunosuppression
(10–16), alterations in health insurance coverage (17–19)
and transitions from pediatric to adult care (14,20–24).
These issues are not unique to pediatric KT recipients,
however. Pediatric LT recipients, as expected, have been
found to have similar difficulties with immunosuppression
adherence, insurance, and care transitions (29–32). While
nonadherence between kidney and liver recipients may not
be identical given the different immunosuppression regi-
mens that are required, one would still expect to find at
least some level of a high–risk agewindow among pediatric
LT recipients, even if attenuated. However, no statistically
appreciable increased risk of graft loss during these ages
was identified among LT recipients.
The absence of a high–risk age window in pediatric LT
recipients may be related to the biologic differences
between kidney and liver grafts. The period of increased
growth during adolescence could lead to hyperfiltration
injury within kidney grafts, and thereby subsequent
increased rates of graft loss, similar to the hyperfiltration
injury thought to occur when kidneys from small donors
are transplanted into large recipients (26). On the other
Figure 2: Hazard of death-censored graft loss across current recipient age (with 95% confidence interval) among pediatric (A) kidney
transplant recipients and (B) liver transplant recipients.
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Figure 3: Hazard of all-cause graft loss (without conditioning on a minimum graft survival of 6 months) across current recipient age (with
95% confidence interval) among pediatric (A) kidney transplant recipients and (B) liver transplant recipients.
Figure 4: Hazard of all-cause graft loss across current recipient age, stratified by donor type and age at transplantation, among pediatric
kidney (A and C) and liver (B and D) transplant recipients.
Graft Loss in Pediatric Liver and Kidney Recipients
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hand, liver grafts may be able to sustain this period of
growth without injury given the concurrent growth of liver
grafts within pediatric recipients as they grow (33,34).
Liver grafts have been shown to develop significant
histologic changes over time though, including signs of
chronic hepatitis and fibrosis (35,36). The exact clinical
relevance of these histologic changes is not entirely clear,
however; nor is it known if the incidence of these changes
peaks within any particular age group, or rather if the
changes just accumulate with a longer duration of time
since transplantation.
The difference in kidney and liver graft loss during the high–
risk age window may also be related to a reduced
susceptibility to immunosuppression withdrawal (or spo-
radic usage) among liver grafts. Indeed, recent success has
been found with early immunosuppression withdrawal
among pediatric LT recipients (37,38). In thisway, our study
could indirectly lend additional support to the promise of
achieving tolerance within pediatric LT recipients. Finally,
and perhaps most likely, the explanation for the difference
in kidney and liver graft loss during the high–risk age
window may be an interaction between any of the
aforementioned potential mechanisms.
Pediatric KT and LT recipients have two other notable
differences that may contribute to the difference in kidney
and liver graft loss seen during the high–risk age window.
Specifically, pediatric LT recipients more frequently
receive deceased donor organs and are generally trans-
planted at younger ages compared to pediatric KT
recipients, highlighting the importance of our sensitivity
analyses showing that inferences were consistent across
donor type and recipient age at transplantation. In
examining graft loss risk stratified by donor type, living
donor organs among pediatric LT recipients, in contrast to
among pediatric KT recipients, appeared to have little
benefit in terms of graft survival compared to deceased
donor organs, consistent with other studies showing
similar graft survival between deceased donor and living
donor LT in pediatric recipients (39,40). This may reflect
differential sensitivity to cold ischemia, importance of
HLAmatching or importance of technical issues related to
graft types or other differences between LT and KT. Also,
stratification by age at transplantation showed that
despite transplantation at different ages, pediatric KT
grafts are most at risk during late adolescence and early
adulthood, in contrast to the relatively stable risk seen
among pediatric LT grafts. This finding further supports
the hypothesis that kidney grafts, regardless of the time
since transplantation, may be especially vulnerable to the
increasing physiologic demands placed on the graft with
the significant growth and maturation that occurs during
late adolescence and early adulthood, a vulnerability that
may be absent or diminished among liver grafts.
Pediatric SLK recipients provide a unique study population
to compare the differential kidney and liver graft loss during
the high–risk age window. SLK recipients essentially
provide the desired counterfactual comparison between
kidney and liver grafts; in other words, SLK recipients
enable comparison of two organs within an otherwise
identical patient in an otherwise identical behavioral,
environmental and social setting (in fact, the same patient
in the same setting). If differential kidney and liver graft loss
within the same patient were to be observed, it would
provide strong evidence that biologic mechanisms in
addition to social mechanisms are likely involved in creating
the high–risk age window seen among pediatric KT
recipients. Although the sample size for SLK recipients in
this study was quite small, a trend towards increased
kidney graft loss compared to liver graft loss during the
high–risk age window did appear.
This study is limited by the small sample size of the SLK
recipient group and the resulting difficulty in providing a
robust statistical comparison between kidney and liver graft
loss in these recipients. However, the large sample sizes
for the KT and LT recipient groups still provide ample and
robust evidence of a clear difference in pediatric kidney and
liver graft loss during the high–risk age window. In addition,
the study is limited by the variables available in the SRTR.
Ideally, graft loss during the high–risk age window could be
compared both across organ type and across varying
degrees of immunosuppression adherence and insurance
coverage. The SRTR unfortunately lacks granularity with
respect to both adherence and insurance status and their
changes over time, as well as other important factors such
as the timing of the care transition process, the specific
immunosuppression regimens used and recipient cognitive
function.
In conclusion, our comparison of graft loss in pediatric KT,
LT and SLK recipients found that the high–risk age window
of late adolescence and early adulthood is significantly less
detrimental in terms of liver graft loss compared to kidney
graft loss. This finding suggests that sociobehavioral
mechanisms alone may be insufficient to create a high–
risk age window after pediatric transplantation. Instead an
interaction between the previously suggested sociobeha-
vioral mechanisms and other biologicmechanisms, such as
differential susceptibility to immunosuppression withdraw-
al, may be responsible for the exceptionally high rate of
graft loss seen among pediatric KT recipients during late
adolescence and early adulthood.
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